



Our previous special edition has analysed the new, typically innovative pharmaceutical technologies that have been submitted but do not yet make the final decision by the National Health Insurance Fund of Hungary (NHIFA) and Ministry of Human Capacities (MoHC). In October 15, 2018 new reimbursed products have been announced including 29 brands, 22 totally new substance and 16 therapeutic areas. These products do not cover all indication areas that are waiting for reimbursement. This analysis focuses only these reimbursed technologies and bases on the data published by the NHIFA on October 05 and 15, 2018. The validity of published data has not been investigated by Healthware.


Number of reimbursed SKUs by reimbursement category



The total number of reimbursed submissions and brands is 57 and 29, respectively.




Average procedure length by reimbursement category (days)²



Number of the reimbursed submission procedures by ATC5 codes²

ATC5	Name	Brands	SKUs
L01XE	Protein kinase inhibitors	6	15
L01XC	Monoclonal antibodies	6	10
L04AC	Interleukin inhibitors	3	7
L04AA	Selective immunosuppressants	4	7
B02BD	Blood coagulation factors	1	5
N05AX	Other antipsychotics	1	4
B01AC	Platelet aggregation inhibitors excl. Heparin	1	2
R03DX	Other systemic drugs for obstructive airway diseases	2	2
J05AP	Direct acting antivirals	1	1
L01XX	Other antineoplastic agents	1	1
L02BX	Other hormone antagonists and related agents	1	1
L04AB	Tumor necrosis factor alpha (TNF-α) inhibitors	1	1
L04AX	Other immunosuppressants	1	1
Total		29	57

Average procedure length by ATC main groups (days)²



MAT NPP (Named Patient Program) turnover by ATC5 codes²


ATC5	Name	Pack turnover (201709-201808)	Reimbursement turnover HUF (EUR*) (201709-201808)
L01XE	Protein kinase inhibitors	2 670	3 909 270 591 (12 133 056)
L01XC	Monoclonal antibodies	6 739	3 862 905 426 (11 989 154)
L04AC	Interleukin inhibitors	2 050	687 167 972 (2 132 737)
L04AA	Selective immunosuppressants	1 098	1 322 540 584 (4 104 719)
B02BD	Blood coagulation factors		
N05AX	Other antipsychotics		
B01AC	Platelet aggregation inhibitors excl. Heparin	10	243 120 (755)
R03DX	Other systemic drugs for obstructive airway diseases	315	110 507 649 (342 978)
J05AP	Direct acting antivirals		
L01XX	Other antineoplastic agents	976	395 387 366 (1 227 149)
L02BX	Other hormone antagonists and related agents		
L04AB	Tumor necrosis factor alpha (TNF-α) inhibitors		
L04AX	Other immunosuppressants		
Total		13 858	10 288 022 708 (31 930 548)

*Exchange rate (16/10/2018): 322,2 HUF/EUR

Top 4 applicants by the number of brands and SKUs²



Top 3 ATC main group by the number of brands and SKUs²



L - Antineop. & immunom.; R - Respiratory; B - Blood


During the NHIFA co-ordinated period, the financing structure for the technology has been determined on the basis of submitted and agreed HTA, BIA and medical considerations. The final decision has been taken by a Committee coordinated by the Ministry.

- All products have been waiting for the final decision more than 90 days.
- From 144 SKUs that have been waiting for the final decision more than 90 days, 57 have been reimbursed since October 15, 2018.
- The average procedure time of the newly reimbursed products is 635 days (min-max: 324 and 1038 days).
- The average procedure time of NHIFA is 204 days (min-max: 21 and 410 days).
- The average procedure time of MoHC is 415 days (min-max: 270 and 738 days).

Analysis of published data has shown that these products already have relevant MAT NPP reimbursement turnover (10,3 billion HUF; 31,9 million EUR). This value is almost the half of the total NPP budget, 2018. It is also important to note that half of the brands belong only to four big international distributors out of eighteen:

- Roche
- Pfizer
- Janssen
- Novartis

With further questions, please contact us!



¹ NHIFA: National Health Insurance Fund of Hungary

² Healthware analysis based on NHIFA data

³ Standard official process period of NHIFA